{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:23:03Z","timestamp":1792304583961,"version":"4.4.0"},"reference-count":342,"publisher":"National Institute for Health and Care Research","issue":"29","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/66\/01"],"award-info":[{"award-number":["14\/66\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n \n The objectives were to evaluate the clinical effectiveness, safety and cost-effectiveness of non-bisphosphonates {denosumab [Prolia\n \u00ae<\/jats:sup>\n ; Amgen Inc., Thousand Oaks, CA, USA], raloxifene [Evista\n \u00ae<\/jats:sup>\n ; Daiichi Sankyo Company, Ltd, Tokyo, Japan], romosozumab [Evenity\n \u00ae<\/jats:sup>\n ; Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and Amgen Inc.] and teriparatide [Forsteo\n \u00ae<\/jats:sup>\n ; Eli Lilly and Company, Indianapolis, IN, USA]}, compared with each other, bisphosphonates or no treatment, for the prevention of fragility fracture.\n <\/jats:p>\n <\/jats:sec>\n \n Data sources<\/jats:title>\n For the clinical effectiveness review, nine electronic databases (including MEDLINE, EMBASE and the World Health Organization International Clinical Trials Registry Platform) were searched up to July 2018.<\/jats:p>\n <\/jats:sec>\n \n Review methods<\/jats:title>\n \n A systematic review and network meta-analysis of fracture and femoral neck bone mineral density were conducted. A review of published economic analyses was undertaken and a model previously used to evaluate bisphosphonates was adapted. Discrete event simulation was used to estimate lifetime costs and quality-adjusted life-years for a simulated cohort of patients with heterogeneous characteristics. This was done for each non-bisphosphonate treatment, a strategy of no treatment, and the five bisphosphonate treatments previously evaluated. The model was populated with effectiveness evidence from the systematic review and network meta-analysis. All other parameters were estimated from published sources. An NHS and Personal Social Services perspective was taken, and costs and benefits were discounted at 3.5% per annum. Fracture risk was estimated from patient characteristics using the QFracture\n \u00ae<\/jats:sup>\n (QFracture-2012 open source revision 38, Clinrisk Ltd, Leeds, UK) and FRAX\n \u00ae<\/jats:sup>\n (web version 3.9, University of Sheffield, Sheffield, UK) tools. The relationship between fracture risk and incremental net monetary benefit was estimated using non-parametric regression. A probabilistic sensitivity analysis and scenario analyses were used to assess uncertainty.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Fifty-two randomised controlled trials of non-bisphosphonates were included in the clinical effectiveness systematic review and an additional 51 randomised controlled trials of bisphosphonates were included in the network meta-analysis. All treatments had beneficial effects compared with placebo for vertebral, non-vertebral and hip fractures, with hazard ratios varying from 0.23 to 0.94, depending on treatment and fracture type. The effects on vertebral fractures and the percentage change in bone mineral density were statistically significant for all treatments. The rate of serious adverse events varied across trials (0\u201333%), with most between-group differences not being statistically significant for comparisons with placebo\/no active treatment, non-bisphosphonates or bisphosphonates. The incremental cost-effectiveness ratios were >\u2009\u00a320,000 per quality-adjusted life-year for all non-bisphosphonate interventions compared with no treatment across the range of QFracture and FRAX scores expected in the population eligible for fracture risk assessment. The incremental cost-effectiveness ratio for denosumab may fall below \u00a330,000 per quality-adjusted life-year at very high levels of risk or for high-risk patients with specific characteristics. Raloxifene was dominated by no treatment (resulted in fewer quality-adjusted life-years) in most risk categories.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n The incremental cost-effectiveness ratios are uncertain for very high-risk patients.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Non-bisphosphonates are effective in preventing fragility fractures, but the incremental cost-effectiveness ratios are generally greater than the commonly applied threshold of \u00a320,000\u201330,000 per quality-adjusted life-year.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42018107651.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 24, No. 29. See the NIHR Journals Library website for further project information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta24290","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T06:35:34Z","timestamp":1593153334000},"page":"1-314","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":160,"title":["Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation"],"prefix":"10.3310","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6609-4287","authenticated-orcid":true,"given":"Sarah","family":"Davis","sequence":"first","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-5979","authenticated-orcid":true,"given":"Emma","family":"Simpson","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-9842","authenticated-orcid":true,"given":"Jean","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-7831","authenticated-orcid":true,"given":"Marrissa Martyn-St","family":"James","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1944-458X","authenticated-orcid":true,"given":"Andrew","family":"Rawdin","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-4794","authenticated-orcid":true,"given":"Ruth","family":"Wong","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-3312","authenticated-orcid":true,"given":"Edward","family":"Goka","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-214X","authenticated-orcid":true,"given":"Neil","family":"Gittoes","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-9268","authenticated-orcid":true,"given":"Peter","family":"Selby","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2020,6]]},"reference":[{"key":"key20200624171440342_ref1-bib1","unstructured":"World Health Organization. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group. WHO Technical Report Series 843. Geneva: WHO; 1994."},{"key":"key20200624171440342_ref1-bib2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","journal-title":"JAMA"},{"key":"key20200624171440342_ref1-bib4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The population burden of fractures originates in women with osteopenia, not osteoporosis","volume":"17","author":"Pasco","year":"2006","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"key20200624171440342_ref1-bib6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch Osteoporos"},{"key":"key20200624171440342_ref1-bib7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11657-011-0063-y","article-title":"Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model","volume":"6","author":"Gauthier","year":"2011","journal-title":"Arch Osteoporos"},{"key":"key20200624171440342_ref1-bib8","volume-title":"Osteoporosis: Assessing the Risk of Fragility Fracture. Clinical Guideline [CG146]","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key20200624171440342_ref1-bib9","volume-title":"Bisphosphonates for Treating Osteoporosis. Technology Appraisal Guidance [TA464]","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"key20200624171440342_ref1-bib10","volume-title":"Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women. Technology Appraisal Guidance [TA204]","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"key20200624171440342_ref1-bib11","volume-title":"Raloxifene and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women [TA161]","author":"National Institute for Heath and Care Excellence","year":"2008"},{"key":"key20200624171440342_ref1-bib12","volume-title":"Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women (Amended) [TA160]","author":"National Institute for Heath and Care Excellence","year":"2011"},{"key":"key20200624171440342_ref1-bib13","volume-title":"NICE Quality Standard 149 on Osteoporosis","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"key20200624171440342_ref1-bib14","volume-title":"NOGG 2017: Clinical Guideline for the Prevention and Treatment of Osteoporosis","author":"National Osteoporosis Guideline Group","year":"2017"},{"key":"key20200624171440342_ref1-bib15","volume-title":"Analyses of the Cost-effectiveness of Pooled Alendronate and Risedronate, Compared with Strontium Ranelate, Raloxifene, Etidronate and Teriparatide","author":"Stevenson","year":"2006"},{"key":"key20200624171440342_ref1-bib16","volume-title":"Unit Costs of Health and Social Care 2017","author":"Curtis","year":"2017"},{"key":"key20200624171440342_ref1-bib17","volume-title":"Osteoporosis Overview \u2013 NICE Pathway","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key20200624171440342_ref1-bib18","volume-title":"Fragility Fracture Risk Assessment \u2013 NICE Pathway","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key20200624171440342_ref1-bib19","unstructured":"National Institute for Health and Care Excellence. Non-bisphosphonates for Treating Osteoporosis: Final Scope. London: NICE; 2018."},{"key":"key20200624171440342_ref1-bib20","unstructured":"Union Chimique Belge (UCB) S.A.. Company Evidence Submission for Romosozumab. Brussels: UCB S.A."},{"key":"key20200624171440342_ref1-bib21","unstructured":"Amgen Ltd. Summary of Product Characteristics for Prolia 60 mg Solution for Injection in Pre-filled Syringe. Electronic Medicines Compendium; 2015. URL: www.medicines.org.uk\/emc\/product\/568\/smpc (accessed 31 October 2018)."},{"key":"key20200624171440342_ref1-bib22","unstructured":"European Medicines Agency. Summary of Opinion 1 (Initial Authorisation) \u2013 Movymia. London: European Medicines Agency; 2016. URL: www.ema.europa.eu\/en\/documents\/product-information\/movymia-epar-product-information_en.pdf (accessed 6 April 2020)."},{"key":"key20200624171440342_ref1-bib23","unstructured":"European Medicines Agency. Summary of Opinion 1 (Initial Authorisation) \u2013 Terrosa. London: European Medicines Agency; 2016. URL: www.ema.europa.eu\/en\/documents\/product-information\/terrosa-epar-product-information_en.pdf (accessed 6 April 2020)."},{"key":"key20200624171440342_ref1-bib24","volume-title":"Summary of Product Characteristics for Evista 60 Mg Film-coated Tablets","author":"Daiichi Sankyo UK Ltd","year":"2018"},{"key":"key20200624171440342_ref1-bib25","volume-title":"Summary of Product Characteristics for Forsteo 20 micrograms\/80 microlitres Solution for Injection in Pre-filled Pen","author":"Eli Lilly and Company Ltd","year":"2018"},{"key":"key20200624171440342_ref1-bib26","volume-title":"Prescription Cost Analysis \u2013 England, 2017 [PAS]","author":"NHS Digital","year":"2017"},{"key":"key20200624171440342_ref1-bib27","volume-title":"Prescribing Costs in Hospitals and the Community, England 2016\/17","author":"NHS Digital","year":"2017"},{"key":"key20200624171440342_ref1-bib28","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20200624171440342_ref1-bib29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","article-title":"Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK","volume":"62","author":"Compston","year":"2009","journal-title":"Maturitas"},{"key":"key20200624171440342_ref1-bib30","volume-title":"Welcome to FRAX\u00ae","author":"Centre for Metabolic Bone Diseases, University of Sheffield","year":"2014"},{"key":"key20200624171440342_ref1-bib31","volume-title":"Welcome to the QFracture\u00ae \u2013 2012 Risk Calculator","author":"ClinRisk Ltd","year":"2012"},{"key":"key20200624171440342_ref1-bib32","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"key20200624171440342_ref1-bib33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"78","key":"key20200624171440342_ref1-bib34","doi-asserted-by":"publisher","DOI":"10.3310\/hta20780","article-title":"A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures","volume":"20","author":"Davis","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20200624171440342_ref1-bib35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib36","volume-title":"Early and Locally Advanced Breast Cancer: Diagnosis and Management","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key20200624171440342_ref1-bib37","volume-title":"Prostate Cancer: Diagnosis and Management","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20200624171440342_ref1-bib38","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 5. 2. 0 (updated June 2017)","author":"Higgins","year":"2017"},{"key":"key20200624171440342_ref1-bib39","volume-title":"Current Version of RoB 2","author":"The Cochrane Collaboration"},{"key":"key20200624171440342_ref1-bib40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0895-4356(03)00155-0","article-title":"Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis","volume":"56","author":"Wright","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"key20200624171440342_ref1-bib41","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib42","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib43","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib44","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib45","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3349\/ymj.2016.57.4.905","article-title":"Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension","volume":"57","author":"Koh","year":"2016","journal-title":"Yonsei Med J"},{"key":"key20200624171440342_ref1-bib46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","article-title":"Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial","volume":"14","author":"Morii","year":"2003","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib48","first-page":"1029","article-title":"Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial","volume":"117","author":"Liu","year":"2004","journal-title":"Chin Med J"},{"key":"key20200624171440342_ref1-bib49","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00774-011-0325-1","article-title":"Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia","volume":"30","author":"Gorai","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"key20200624171440342_ref1-bib50","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib51","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"key20200624171440342_ref1-bib52","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","article-title":"Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial","volume":"13","author":"Lufkin","year":"1998","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib53","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/ard.2010.143453","article-title":"Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial","volume":"70","author":"Mok","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20200624171440342_ref1-bib54","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib56","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","article-title":"Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases","volume":"47","author":"Miyauchi","year":"2010","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib59","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00774-008-0871-3","article-title":"Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study","volume":"26","author":"Miyauchi","year":"2008","journal-title":"J Bone Miner Metab"},{"key":"key20200624171440342_ref1-bib60","article-title":"Effects of abaloparatide on vertebral and non-vertebral fracture incidence in postmenopausal women with osteoporosis-results of the phase 3 active trial","volume":"36","author":"Miller","year":"2015","journal-title":"EndocrineReviews"},{"key":"key20200624171440342_ref1-bib61","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib62","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib63","first-page":"418","article-title":"Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis \u2013 an Indian experience","volume":"56","author":"Sethi","year":"2008","journal-title":"J Assoc Physicians India"},{"key":"key20200624171440342_ref1-bib64","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"key20200624171440342_ref1-bib65","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"key20200624171440342_ref1-bib66","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib67","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"key20200624171440342_ref1-bib68","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib71","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","article-title":"Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate","volume":"22","author":"Kendler","year":"2011","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib72","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib73","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key20200624171440342_ref1-bib74","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20200624171440342_ref1-bib75","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib76","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","article-title":"Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International","volume":"255","author":"Sambrook","year":"2004","journal-title":"J Intern Med"},{"key":"key20200624171440342_ref1-bib77","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.GME.0000119981.77837.1F","article-title":"Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis","volume":"11","author":"Luckey","year":"2004","journal-title":"Menopause"},{"key":"key20200624171440342_ref1-bib78","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib79","first-page":"97","article-title":"Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study","volume":"8","author":"Muscoso","year":"2004","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20200624171440342_ref1-bib80","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib81","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/13697137.2010.537408","article-title":"Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis","volume":"14","author":"Sanad","year":"2011","journal-title":"Climacteric"},{"key":"key20200624171440342_ref1-bib82","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalsk\u00e1","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib83","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib84","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"key20200624171440342_ref1-bib85","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20200624171440342_ref1-bib86","doi-asserted-by":"publisher","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"key":"key20200624171440342_ref1-bib87","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial","volume":"28","author":"Gl\u00fcer","year":"2013","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib88","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int J Clin Pract"},{"key":"key20200624171440342_ref1-bib89","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"key20200624171440342_ref1-bib90","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib91","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib92","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jbmr.3067","article-title":"Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial","volume":"32","author":"Malouf-Sierra","year":"2017","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib94","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00774-009-0112-4","article-title":"Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and\/or alfacalcidol in postmenopausal Japanese women","volume":"28","author":"Gorai","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"key20200624171440342_ref1-bib95","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"key20200624171440342_ref1-bib96","volume-title":"Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis","author":"ClinicalTrials.gov","year":"2008"},{"key":"key20200624171440342_ref1-bib97","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","article-title":"Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis","volume":"130","author":"Simpson","year":"2020","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib98","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.2106\/JBJS.15.01217","article-title":"Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: results of a randomized, active-controlled, double-blind clinical trial at 26 weeks","volume":"98","author":"Aspenberg","year":"2016","journal-title":"J Bone Joint Surg Am"},{"key":"key20200624171440342_ref1-bib99","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2017","journal-title":"Lancet"},{"key":"key20200624171440342_ref1-bib100","unstructured":"Amgen Inc. Company Evidence Submission for Denosumab. Thousand Oaks, CA: Amgen Inc."},{"key":"key20200624171440342_ref1-bib101","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.ijom.2016.09.001","article-title":"Randomised trial of bisphosphonate-coated dental implants: radiographic follow-up after five years of loading","volume":"45","author":"Abtahi","year":"2016","journal-title":"Int J Oral Maxillofac Surg"},{"key":"key20200624171440342_ref1-bib102","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","article-title":"Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis","volume":"162","author":"Maricic","year":"2002","journal-title":"Arch Intern Med"},{"key":"key20200624171440342_ref1-bib103","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib104","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20200624171440342_ref1-bib105","volume-title":"Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis","author":"ClinicalTrials.gov","year":"2007"},{"key":"key20200624171440342_ref1-bib106","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib107","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib108","first-page":"S14","article-title":"Teriparatide seems to improve recovery after pertrochanteric hip fracture: comparison with risedronate in a randomized, controlled trial","volume":"26","author":"Aspenberg","year":"2016","journal-title":"HIPInt"},{"key":"key20200624171440342_ref1-bib109","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"OsteoporosInt"},{"key":"key20200624171440342_ref1-bib110","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab And Teriparatide Administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib111","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib112","volume-title":"CHMP Assessment Report for Prolia","author":"European Medicines Agency","year":"2010"},{"key":"key20200624171440342_ref1-bib113","volume-title":"CHMP Assessment Report for Evista","author":"European Medicines Agency","year":"2009"},{"key":"key20200624171440342_ref1-bib114","volume-title":"EPAR Scientific Discussion for Forsteo","author":"European Medicines Agency","year":"2005"},{"key":"key20200624171440342_ref1-bib115","volume-title":"Summary of Product Characteristics for Forsteo","author":"European Medicines Agency","year":"2016"},{"key":"key20200624171440342_ref1-bib116","first-page":"S14","article-title":"Evaluation of health-related quality of life in postmenopausal women with osteoporosis who participated in the freedom trial","volume":"21","author":"Silverman","year":"2010","journal-title":"OsteoporosInt"},{"key":"key20200624171440342_ref1-bib117","volume-title":"Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women","author":"ClinicalTrials.gov","year":"2005"},{"key":"key20200624171440342_ref1-bib118","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00198-011-1720-0","article-title":"Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib119","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"key20200624171440342_ref1-bib120","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/0272989X18759488","article-title":"Incorporating genuine prior information about between-study heterogeneity in random effects pairwise and network meta-analyses","volume":"38","author":"Ren","year":"2018","journal-title":"Med Decis Making"},{"key":"key20200624171440342_ref1-bib121","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity \u2013 subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"key20200624171440342_ref1-bib122","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/sim.5539","article-title":"Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis","volume":"32","author":"Achana","year":"2013","journal-title":"Stat Med"},{"key":"key20200624171440342_ref1-bib123","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"key20200624171440342_ref1-bib124","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS \u2013 a Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Computing"},{"key":"key20200624171440342_ref1-bib125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v012.i03","article-title":"R2WinBUGS: a package for running WinBUGS from R","volume":"12","author":"Sturtz","year":"2005","journal-title":"J StatSoftw"},{"key":"key20200624171440342_ref1-bib126","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"key":"key20200624171440342_ref1-bib127","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J Royal Stat Soc"},{"key":"key20200624171440342_ref1-bib128","volume-title":"A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture (MOVE)","author":"ClinicalTrials.gov","year":"2015"},{"key":"key20200624171440342_ref1-bib129","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00044011-200424060-00003","article-title":"Weekly oral alendronic Acid in male osteoporosis","volume":"24","author":"Miller","year":"2004","journal-title":"Clin Drug Investig"},{"key":"key20200624171440342_ref1-bib130","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","article-title":"Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)","volume":"28","author":"Nakamura","year":"2017","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib131","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1742-1241.2001.tb11111.x","article-title":"Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis","volume":"55","author":"Dursun","year":"2001","journal-title":"Int J Clin Pract"},{"key":"key20200624171440342_ref1-bib132","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric"},{"key":"key20200624171440342_ref1-bib133","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib134","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib135","first-page":"106","article-title":"Effect of treatment of postmenopausal osteoporosis with continuous daily oral alendronate and the incidence of fractures","volume":"157","author":"Carfora","year":"1998","journal-title":"Gazzetta Medica Ital Arch per le Sci Mediche"},{"key":"key20200624171440342_ref1-bib136","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib137","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib138","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jcpt.12429","article-title":"Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis","volume":"41","author":"Tan","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"key20200624171440342_ref1-bib139","unstructured":"National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013."},{"issue":"36","key":"key20200624171440342_ref1-bib140","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20200624171440342_ref1-bib141","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00198-004-1688-0","article-title":"Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"issue":"29","key":"key20200624171440342_ref1-bib142","doi-asserted-by":"publisher","DOI":"10.3310\/hta6290","article-title":"Treatment of established osteoporosis: a systematic review and cost-utility analysis","volume":"6","author":"Kanis","year":"2002","journal-title":"Health Technol Assess"},{"issue":"22","key":"key20200624171440342_ref1-bib143","doi-asserted-by":"publisher","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess"},{"key":"key20200624171440342_ref1-bib144","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","article-title":"The cost-effectiveness of alendronate in the management of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib145","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2165\/11589310-000000000-00000","article-title":"Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal","volume":"29","author":"Scotland","year":"2011","journal-title":"PharmacoEconomics"},{"key":"key20200624171440342_ref1-bib146","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00198-012-2115-6","article-title":"Intervention thresholds for denosumab in the UK using a FRAX-based cost-effectiveness analysis","volume":"24","author":"Strom","year":"2013","journal-title":"OsteoporosInt"},{"key":"key20200624171440342_ref1-bib147","doi-asserted-by":"publisher","DOI":"10.3310\/hta15suppl1\/06","article-title":"Denosumab for the prevention of osteoporotic fractures in postmenopausal women","volume":"15","author":"Waugh","year":"2011","journal-title":"Health Technol Assess"},{"key":"key20200624171440342_ref1-bib148","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"key20200624171440342_ref1-bib149","volume-title":"Analyses of the Cost Effectiveness of Pooled Alendronate and Risedronate, Compared with Strontium Ranelate, Raloxifene, Etidronate and Teriparatide","author":"Stevenson","year":"2006"},{"key":"key20200624171440342_ref1-bib150","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00198-007-0429-6","article-title":"Excess mortality following hip fracture: the role of underlying health status","volume":"18","author":"Tosteson","year":"2007","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib151","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: a systematic epidemiological review","volume":"20","author":"Abrahamsen","year":"2009","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib152","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","article-title":"Mortality after osteoporotic fractures","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib153","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","article-title":"Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis","volume":"22","author":"J\u00f6nsson","year":"2011","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib154","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00198-003-1494-0","article-title":"Mortality and pulmonary embolism after fracture in the elderly","volume":"14","author":"Barrett","year":"2003","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib155","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","article-title":"Excess mortality after hospitalisation for vertebral fracture","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib156","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","article-title":"The components of excess mortality after hip fracture","volume":"32","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib157","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","article-title":"What is the true mortality of hip fractures?","volume":"105","author":"Parker","year":"1991","journal-title":"Public Health"},{"key":"key20200624171440342_ref1-bib158","volume-title":"Anglian Audit of Hip Fracture 2","author":"Todd","year":"1999"},{"key":"key20200624171440342_ref1-bib159","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"key":"key20200624171440342_ref1-bib160","volume-title":"Bisphosphonates for Preventing Osteoporotic Fragility Fractures (Including a Partial Update of NICE Technology Appraisal Guidance 160 and 161). Addendum","author":"Davis","year":"2017"},{"key":"key20200624171440342_ref1-bib161","volume-title":"National Life Tables, England 2011\u20132013","author":"Office for National Statistics","year":"2014"},{"key":"key20200624171440342_ref1-bib162","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1524-4733.2007.00188.x","article-title":"The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks","volume":"10","author":"van Staa","year":"2007","journal-title":"Value Health"},{"key":"key20200624171440342_ref1-bib163","doi-asserted-by":"publisher","first-page":"b4229","DOI":"10.1136\/bmj.b4229","article-title":"Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores","volume":"339","author":"Hippisley-Cox","year":"2009","journal-title":"BMJ"},{"key":"key20200624171440342_ref1-bib164","doi-asserted-by":"publisher","first-page":"e3427","DOI":"10.1136\/bmj.e3427","article-title":"Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study","volume":"344","author":"Hippisley-Cox","year":"2012","journal-title":"BMJ"},{"key":"key20200624171440342_ref1-bib165","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz","year":"2010","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib166","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/acr.21638","article-title":"Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key20200624171440342_ref1-bib167","doi-asserted-by":"publisher","first-page":"i23","DOI":"10.1093\/rheumatology\/keq708","article-title":"Non-persistence to anti-osteoporosis medications in the UK using the General Practice Research Database (GPRD)","volume":"49","author":"Li","year":"2010","journal-title":"Rheumatology"},{"key":"key20200624171440342_ref1-bib168","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/gme.0b013e318221bacd","article-title":"Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database","volume":"19","author":"Li","year":"2012","journal-title":"Menopause"},{"key":"key20200624171440342_ref1-bib169","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","article-title":"Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study","volume":"26","author":"Hadji","year":"2015","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib170","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","article-title":"Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis","volume":"26","author":"Karlsson","year":"2015","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib171","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11657-018-0491-z","article-title":"Persistence at 24\u2009months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study","volume":"13","author":"Silverman","year":"2018","journal-title":"Arch Osteoporos"},{"key":"key20200624171440342_ref1-bib172","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","article-title":"Persistence with teriparatide in patients with osteoporosis: the UK experience","volume":"17","author":"Arden","year":"2006","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib173","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00198-008-0788-7","article-title":"Teriparatide in men: persistence and geographical variation in the UK","volume":"20","author":"Abhishek","year":"2009","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib174","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","article-title":"Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo\u00ae Observational Study (ExFOS)","volume":"103","author":"Napoli","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"key20200624171440342_ref1-bib175","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4081\/reumatismo.2013.22","article-title":"Duration of treatment for osteoporosis","volume":"65","author":"Idolazzi","year":"2013","journal-title":"Reumatismo"},{"key":"key20200624171440342_ref1-bib176","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib177","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"key20200624171440342_ref1-bib178","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1210\/jc.2011-0412","article-title":"Effect of stopping risedronate after long-term treatment on bone turnover","volume":"96","author":"Eastell","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib179","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib180","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","article-title":"Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment","volume":"22","author":"Ravn","year":"1998","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib181","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20200624171440342_ref1-bib182","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib183","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"key":"key20200624171440342_ref1-bib184","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib185","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib186","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.bone.2009.10.043","article-title":"The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women","volume":"46","author":"Naylor","year":"2010","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib187","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib188","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib189","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib190","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"key20200624171440342_ref1-bib191","unstructured":"NHS Prescription Services. The Electronic Drug Tariff (online). London: Department of Health and Social Care; 2018. URL: www.drugtariff.nhsbsa.nhs.uk\/#\/00446515-DC_2\/DC00446511\/Home (accessed 6 November 2018)."},{"key":"key20200624171440342_ref1-bib192","unstructured":"Commercial Medicines Unit. eMit National Database (online). London: Department of Health and Social Care; 2017. URL: www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit (accessed 6 November 2018)."},{"key":"key20200624171440342_ref1-bib193","unstructured":"Department of Health and Social Care. National Schedule of Reference Costs \u2013 Year 2015\/16 \u2013 NHS Trusts and NHS Foundation Trusts. London: Department of Health and Social Care; 2016."},{"key":"key20200624171440342_ref1-bib194","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ejhpharm-2015-000742","article-title":"Setting up a homecare service for zoledronic acid treatment of osteoporosis","volume":"23","author":"Wong","year":"2016","journal-title":"Eur J Hosp Pharm"},{"key":"key20200624171440342_ref1-bib195","doi-asserted-by":"publisher","first-page":"e82694","DOI":"10.1371\/journal.pone.0082694","article-title":"Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I. II trials","volume":"9","author":"Mason","year":"2014","journal-title":"PLOS ONE"},{"key":"key20200624171440342_ref1-bib196","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","author":"Boquete-Castro","year":"2016","journal-title":"Clin Oral Implants Res"},{"key":"key20200624171440342_ref1-bib197","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib198","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00774-011-0299-z","article-title":"An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence","volume":"30","author":"Malden","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"key20200624171440342_ref1-bib199","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"key20200624171440342_ref1-bib200","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","article-title":"Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013","volume":"75","author":"Compston","year":"2013","journal-title":"Maturitas"},{"key":"key20200624171440342_ref1-bib201","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","article-title":"Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw","volume":"16","author":"Miksad","year":"2011","journal-title":"Oncologist"},{"issue":"63","key":"key20200624171440342_ref1-bib202","doi-asserted-by":"publisher","DOI":"10.3310\/hta23630","article-title":"Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation","volume":"23","author":"Pandor","year":"2019","journal-title":"Health Technol Assess"},{"key":"key20200624171440342_ref1-bib203","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3111\/13696998.2010.547967","article-title":"Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom","volume":"14","author":"Guti\u00e9rrez","year":"2011","journal-title":"J Med Econ"},{"key":"key20200624171440342_ref1-bib204","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.bone.2012.05.020","article-title":"Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom","volume":"51","author":"Guti\u00e9rrez","year":"2012","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib205","unstructured":"Department of Health and Social Care. National Schedule of Reference Costs \u2013 Year 2013\/14. London: Department of Health and Social Care; 2015."},{"key":"key20200624171440342_ref1-bib206","volume-title":"Unit Costs of Health and Social Care 2014","author":"Curtis","year":"2014"},{"key":"key20200624171440342_ref1-bib207","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3111\/13696998.2014.959588","article-title":"Retrospective database study to assess the economic impact of hip fracture in the United Kingdom","volume":"17","author":"Lambrelli","year":"2014","journal-title":"J Med Econ"},{"key":"key20200624171440342_ref1-bib208","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00198-015-3277-9","article-title":"Impact of hip fracture on hospital care costs: a population-based study","volume":"27","author":"Leal","year":"2016","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib209","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","article-title":"Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS","volume":"29","author":"Svedbom","year":"2018","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib210","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00198-015-3088-z","article-title":"Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS)","volume":"26","author":"Abimanyi-Ochom","year":"2015","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib211","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/a: 1015632114068","article-title":"Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol","volume":"11","author":"Tidermark","year":"2002","journal-title":"Qual Life Res"},{"key":"key20200624171440342_ref1-bib212","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00198-016-3544-4","article-title":"Quality of life, resource use, and costs related to hip fracture in Estonia","volume":"27","author":"J\u00fcrisson","year":"2016","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib213","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11136-017-1748-5","article-title":"Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS","volume":"27","author":"Svedbom","year":"2018","journal-title":"Qual Life Res"},{"key":"key20200624171440342_ref1-bib214","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib215","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: a systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"key20200624171440342_ref1-bib216","doi-asserted-by":"publisher","first-page":"65","DOI":"10.11005\/jbm.2017.24.1.65","article-title":"Current role and application of teriparatide in fracture healing of osteoporotic patients: a systematic review","volume":"24","author":"Kim","year":"2017","journal-title":"J Bone Metab"},{"key":"key20200624171440342_ref1-bib217","doi-asserted-by":"publisher","first-page":"e0168691","DOI":"10.1371\/journal.pone.0168691","article-title":"Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis","volume":"11","author":"Shi","year":"2016","journal-title":"PLOS ONE"},{"key":"key20200624171440342_ref1-bib218","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","article-title":"Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis","volume":"27","author":"Beaudoin","year":"2016","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib219","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00198-014-2838-7","article-title":"A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia","volume":"26","author":"Chen","year":"2015","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib220","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ando.2015.10.009","article-title":"Efficacy and safety of denosumab for the treatment of osteoporosis: a systematic review","volume":"76","author":"Di\u00e9dhiou","year":"2015","journal-title":"Ann Endocrinol"},{"key":"key20200624171440342_ref1-bib221","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2147\/CIA.S70307","article-title":"Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)","volume":"9","author":"Fujiwara","year":"2014","journal-title":"Clin Interv Aging"},{"key":"key20200624171440342_ref1-bib222","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1590\/S1516-31802008000500007","article-title":"Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review","volume":"126","author":"Trevisani","year":"2008","journal-title":"Sao Paulo Med J"},{"key":"key20200624171440342_ref1-bib223","doi-asserted-by":"publisher","first-page":"s592","DOI":"10.1590\/S0102-311X2008001600011","article-title":"Treatment of postmenopausal osteoporosis in women: a systematic review","volume":"24","author":"Brand\u00e3o","year":"2008","journal-title":"Cad Saude Publica"},{"key":"key20200624171440342_ref1-bib224","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-010-9420-x","article-title":"Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review","volume":"87","author":"Gallacher","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"key20200624171440342_ref1-bib225","doi-asserted-by":"publisher","first-page":"796510","DOI":"10.1155\/2014\/796510","article-title":"Alendronate versus raloxifene for postmenopausal women: a meta-analysis of seven head-to-head randomized controlled trials","volume":"2014","author":"Lin","year":"2014","journal-title":"Int J Endocrinol"},{"key":"key20200624171440342_ref1-bib226","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med"},{"key":"key20200624171440342_ref1-bib227","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.25011\/cim.v40i3.28394","article-title":"Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis","volume":"40","author":"Liu","year":"2017","journal-title":"Clin Invest Med"},{"key":"key20200624171440342_ref1-bib228","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","journal-title":"J Cell Biochem"},{"key":"key20200624171440342_ref1-bib229","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib230","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00198-017-4175-0","article-title":"Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis","volume":"28","author":"Saito","year":"2017","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib231","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"key":"key20200624171440342_ref1-bib232","doi-asserted-by":"publisher","first-page":"e6970","DOI":"10.1097\/MD.0000000000006970","article-title":"Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"key":"key20200624171440342_ref1-bib233","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1302\/2046-3758.67.BJR-2016-0292.R1","article-title":"The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: Which therapies work best? a network meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Bone Joint Res"},{"key":"key20200624171440342_ref1-bib234","doi-asserted-by":"publisher","first-page":"e5496","DOI":"10.1097\/MD.0000000000005496","article-title":"The effect of sequential therapy for postmenopausal women with osteoporosis: a PRISMA-compliant meta-analysis of randomized controlled trials","volume":"95","author":"Lou","year":"2016","journal-title":"Medicine"},{"key":"key20200624171440342_ref1-bib235","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00198-015-3476-4","article-title":"Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis","volume":"27","author":"Amiche","year":"2016","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib236","doi-asserted-by":"publisher","first-page":"e0128032","DOI":"10.1371\/journal.pone.0128032","article-title":"Comparison of bone mineral density in lumbar spine and fracture rate among eight drugs in treatments of osteoporosis in men: a network meta-analysis","volume":"10","author":"Chen","year":"2015","journal-title":"PLOS ONE"},{"key":"key20200624171440342_ref1-bib237","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","article-title":"Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis","volume":"24","author":"Freemantle","year":"2013","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib238","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of osteoporosis treatment on mortality: a meta-analysis","volume":"95","author":"Bolland","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib239","doi-asserted-by":"publisher","first-page":"e1674","DOI":"10.1097\/MD.0000000000001674","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteoporosis: a meta-analysis","volume":"94","author":"Gu","year":"2015","journal-title":"Medicine"},{"key":"key20200624171440342_ref1-bib240","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han","year":"2012","journal-title":"Int J Clin Pract"},{"key":"key20200624171440342_ref1-bib241","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"key":"key20200624171440342_ref1-bib242","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00774-011-0313-5","article-title":"Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis","volume":"30","author":"Nakamura","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"key20200624171440342_ref1-bib243","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00223-011-9564-3","article-title":"Effects of increasing age, dosage, and duration of PTH treatment on BMD increase \u2013 a meta-analysis","volume":"90","author":"Schwarz","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"key20200624171440342_ref1-bib244","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.semarthrit.2011.03.005","article-title":"Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis","volume":"41","author":"von Keyserlingk","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"key20200624171440342_ref1-bib245","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.afos.2016.03.003","article-title":"Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis","volume":"2","author":"Benjamin","year":"2016","journal-title":"Osteoporos Sarcopenia"},{"key":"key20200624171440342_ref1-bib246","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1345\/aph.1Q543","article-title":"Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis","volume":"46","author":"Sutton","year":"2012","journal-title":"Ann Pharmacother"},{"key":"key20200624171440342_ref1-bib247","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3821\/1913-701X-144.2.72","article-title":"Denosumab: a new injectable treatment for postmenopausal osteoporosis","volume":"144","author":"Whelan","year":"2011","journal-title":"Can Pharm J"},{"key":"key20200624171440342_ref1-bib248","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/ard.2009.112920","article-title":"Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates","volume":"69","author":"Dore","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20200624171440342_ref1-bib249","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib250","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib251","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20200624171440342_ref1-bib252","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"key20200624171440342_ref1-bib253","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1200\/jco.2014.32.15_suppl.5075","article-title":"Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: results from a Phase III trial of denosumab for the prevention of skeletal-related events","volume":"32","author":"Klotz","year":"2014","journal-title":"J ClinOncol"},{"key":"key20200624171440342_ref1-bib254","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20200624171440342_ref1-bib255","doi-asserted-by":"publisher","first-page":"9133","DOI":"10.1200\/jco.2010.28.15_suppl.9133","article-title":"Delaying skeletal-related events in a randomized Phase III study of denosumab versus zoledronic acid in patients with advanced cancer","volume":"28","author":"Henry","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200624171440342_ref1-bib256","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1210\/jc.2013-4105","article-title":"Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa","volume":"99","author":"Fazeli","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib257","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib258","first-page":"ii304","article-title":"FP668A randomized open-label clinical trial examining the effect of denosumab on the prevention of 1st-year bone mineral density loss after renal transplantation (POSTOP study; NCT01377467)","volume":"27","author":"Bonani","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"key":"key20200624171440342_ref1-bib259","first-page":"461","article-title":"Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5","volume":"8","author":"Haghverdi","year":"2014","journal-title":"Iran J Kidney Dis"},{"key":"key20200624171440342_ref1-bib260","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/0148607117695247","article-title":"Denosumab improves bone mineral density in patients with intestinal failure receiving home parenteral nutrition: results from a randomized, controlled clinical trial","volume":"42","author":"Szczepanek","year":"2017","journal-title":"JPEN J Parenter Enter Nutr"},{"key":"key20200624171440342_ref1-bib261","article-title":"Efficacy and safety of denosumab in Chinese postmenopausal women with osteoporosis at increased risk of fracture: results from a 12-month, randomized, double-blind, placebo-controlled phase III study","volume":"31","author":"Zhu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib262","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1530\/boneabs.3.PP356","article-title":"Changes in lumbar spine QCT, DXA and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausal women with low bone mass","volume":"25","author":"Thomas","year":"2014","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib263","first-page":"S150","article-title":"Denosumab significantly increases BMD compared with alendronate in postmenopausal women","volume":"26","author":"Galesanu","year":"2015","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib264","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00774-013-0505-2","article-title":"Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial","volume":"32","author":"Nakano","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"key20200624171440342_ref1-bib265","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00198-007-0475-0","article-title":"Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy","volume":"19","author":"Cosman","year":"2008","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib266","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib267","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib268","doi-asserted-by":"publisher","first-page":"iii235","DOI":"10.1093\/ndt\/gfx147.SP365","article-title":"Comparison of the efficacy of denosumab and alendronate in glucocorticoid-induced osteoporosis","volume":"32","author":"Iseri","year":"2017","journal-title":"Nephrol Dialy Transplant"},{"key":"key20200624171440342_ref1-bib269","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3349\/ymj.2008.49.1.119","article-title":"Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis","volume":"49","author":"Iwamoto","year":"2008","journal-title":"Yonsei Med J"},{"key":"key20200624171440342_ref1-bib270","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib271","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/annrheumdis-2014-eular.3767","article-title":"Denosumab for patients receiving long-term glucocorticoids who do not have adequate response to bisphosphonate treatment: a randomized controlled trial","volume":"73","author":"Mok","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20200624171440342_ref1-bib272","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00198-006-0157-3","article-title":"Teriparatide\u2019s effects on quantitative ultrasound parameters and bone density in women with established osteoporosis","volume":"17","author":"Gonnelli","year":"2006","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib273","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib274","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1507\/endocrj.K07E-027","article-title":"Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis","volume":"55","author":"Majima","year":"2008","journal-title":"Endocr J"},{"key":"key20200624171440342_ref1-bib275","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib276","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1210\/jc.2012-1262","article-title":"Skeletal Histomorphometry in subjects On Teriparatide or Zoledronic acid therapy (SHOTZ) study: a randomized controlled trial","volume":"97","author":"Dempster","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib277","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/0300060513480917","article-title":"Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women","volume":"41","author":"Bai","year":"2013","journal-title":"J Int Med Res"},{"key":"key20200624171440342_ref1-bib278","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib279","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib280","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"key20200624171440342_ref1-bib281","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"key20200624171440342_ref1-bib282","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1210\/jcem.85.2.6393","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate\/Estrogen Study Group","volume":"85","author":"Bone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib283","doi-asserted-by":"publisher","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial","volume":"136","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"key20200624171440342_ref1-bib284","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial","volume":"289","author":"Greenspan","year":"2003","journal-title":"JAMA"},{"key":"key20200624171440342_ref1-bib285","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1345\/aph.1E580","article-title":"Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women","volume":"39","author":"Ho","year":"2005","journal-title":"Ann Pharmacother"},{"key":"key20200624171440342_ref1-bib286","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib287","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib288","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib289","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44: 1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20200624171440342_ref1-bib290","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE","volume":"21","author":"Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"key20200624171440342_ref1-bib291","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bone.2008.09.011","article-title":"Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss","volume":"44","author":"McClung","year":"2009","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib292","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20200624171440342_ref1-bib293","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol"},{"key":"key20200624171440342_ref1-bib294","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib295","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib296","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key20200624171440342_ref1-bib297","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1210\/jcem.85.5.6603","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib298","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"key20200624171440342_ref1-bib299","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"key20200624171440342_ref1-bib300","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib301","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib302","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bone.2004.10.014","article-title":"The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study","volume":"36","author":"Leung","year":"2005","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib303","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib304","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"key":"key20200624171440342_ref1-bib305","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"key":"key20200624171440342_ref1-bib306","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib307","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib308","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s00198-010-1514-9","article-title":"Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial","volume":"22","author":"Adachi","year":"2011","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib309","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/jbmr.1605","article-title":"Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib310","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet Gynecol"},{"key":"key20200624171440342_ref1-bib311","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1185\/030079908x253889","article-title":"Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study","volume":"24","author":"Miller","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key20200624171440342_ref1-bib312","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00296-004-0544-z","article-title":"Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Sarioglu","year":"2006","journal-title":"Rheumatol Int"},{"key":"key20200624171440342_ref1-bib313","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key20200624171440342_ref1-bib314","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200624171440342_ref1-bib315","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-international","volume":"26","author":"Reid","year":"2006","journal-title":"Clinical Drug Investigation"},{"key":"key20200624171440342_ref1-bib316","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","article-title":"A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International","volume":"62","author":"Reid","year":"2008","journal-title":"Int J Clin Pract"},{"key":"key20200624171440342_ref1-bib317","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.bone.2009.01.212","article-title":"Once-yearly treatment with zoledronic acid continues to be effective in old age","volume":"44","author":"Reid","year":"2009","journal-title":"Bone"},{"key":"key20200624171440342_ref1-bib318","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"key20200624171440342_ref1-bib319","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","article-title":"Canadian Urology Research Consortium. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study","volume":"63","author":"Klotz","year":"2013","journal-title":"Eur Urol"},{"key":"key20200624171440342_ref1-bib320","first-page":"86","article-title":"The efficacy and safety of Calidron tablets for management of osteoporosis in Jordanian women: a randomised clinical trial","volume":"12","author":"Shilbayeh","year":"2004","journal-title":"Saudi Pharm J"},{"key":"key20200624171440342_ref1-bib321","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1191\/1479972304cd025oa","article-title":"Randomized controlled trial of alendronate in airways disease and low bone mineral density","volume":"1","author":"Smith","year":"2004","journal-title":"Chron Respir Dis"},{"key":"key20200624171440342_ref1-bib322","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20200624171440342_ref1-bib323","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.ijrobp.2011.06.086","article-title":"Double-blinded, placebo-controlled randomized study evaluating the efficacy of risedronate to prevent the loss of bone mineral density in non-metastatic prostate cancer patients undergoing radiotherapy plus 2\u20133 years of androgen ablation therapy","volume":"81","author":"Choo","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20200624171440342_ref1-bib324","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"key20200624171440342_ref1-bib325","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/j.1464-410X.2010.09329.x","article-title":"Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer","volume":"106","author":"Taxel","year":"2010","journal-title":"BJU Int"},{"key":"key20200624171440342_ref1-bib326","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/BF02850205","article-title":"Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis","volume":"23","author":"Atmaca","year":"2006","journal-title":"Adv Ther"},{"key":"key20200624171440342_ref1-bib327","first-page":"S192","article-title":"The Rapid Onset and Sustained Efficacy (ROSE) study: zoledronic acid vs. alendronate","volume":"21","author":"Hadji","year":"2010","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib328","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00198-011-1583-4","article-title":"Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib329","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1023\/A:1008934208764","article-title":"The Osteoporosis Assessment Questionnaire (OPAQ): a reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis","volume":"9","author":"Silverman","year":"2000","journal-title":"Qual Life Res"},{"key":"key20200624171440342_ref1-bib330","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1477-7525-1-41","article-title":"The Women\u2019s Health Questionnaire (WHQ): Frequently Asked Questions (FAQ)","volume":"1","author":"Hunter","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"key20200624171440342_ref1-bib331","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s001980050210","article-title":"Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis","volume":"10","author":"Lips","year":"1999","journal-title":"Osteoporos Int"},{"key":"key20200624171440342_ref1-bib332","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"key20200624171440342_ref1-bib333","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"key":"key20200624171440342_ref1-bib334","volume-title":"Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis (DIRECT)","author":"ClinicalTrials.gov","year":"2008"},{"key":"key20200624171440342_ref1-bib335","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.3288","article-title":"Treatment of postmenopausal women with osteoporosis for six years with denosumab: three-year results from the freedom extension","volume":"71","author":"Chapurlat","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20200624171440342_ref1-bib336","volume-title":"Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis","author":"ClinicalTrials.gov","year":"2007"},{"key":"key20200624171440342_ref1-bib337","volume-title":"Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density","author":"ClinicalTrials.gov","year":"2007"},{"key":"key20200624171440342_ref1-bib338","volume-title":"Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids (GIOP)","author":"ClinicalTrials.gov","year":"2012"},{"key":"key20200624171440342_ref1-bib339","volume-title":"Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis","author":"ClinicalTrials.gov","year":"2012"},{"key":"key20200624171440342_ref1-bib340","volume-title":"Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis","author":"ClinialTrials.gov","year":"2003"},{"key":"key20200624171440342_ref1-bib341","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/01.ogx.0000310357.43258.f1","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"63","author":"Saag","year":"2008","journal-title":"Obstetrical Gynecological Survey"},{"key":"key20200624171440342_ref1-bib342","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1302\/0301-620X.97B3.35738","article-title":"Recovery of health-related quality of life in a United Kingdom hip fracture population. The Warwick Hip Trauma Evaluation \u2013 a prospective cohort study","volume":"97","author":"Griffin","year":"2015","journal-title":"Bone Joint J"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta24290\/hta24290.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2032874","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2032874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:50:28Z","timestamp":1696276228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta24290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":342,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["10.3310\/hta24290"],"URL":"https:\/\/doi.org\/10.3310\/hta24290","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738246248.793584767","asserted-by":"object"}]},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"8-2018","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"7-2019","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"2-2020","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}